Application of quality by design elements for the development and optimization of an analytical method for protamine sulfate

Journal of Pharmaceutical and Biomedical Analysis

Volumn 62, Issue , 2012, Pages 61-67

  Awotwe Otoo, David ^a,b   Agarabi, Cyrus ^a   Faustino, Patrick J ^a   Habib, Muhammad J ^b   Lee, Sau ^a   Khan, Mansoor A ^a   Shah, Rakhi B ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b HOWARD UNIVERSITY   (United States)

Author keywords

Box Behnken; Design of experiments; HPLC; Optimization; Protamine sulfate

Indexed keywords

METHANOL; PROTAMINE SULFATE;

ARTICLE; BOX BEHNKEN EXPERIMENTAL DESIGN; CONCENTRATION (PARAMETERS); EXPERIMENTAL DESIGN; FLOW RATE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; PH; PLACKETT BURMAN EXPERIMENTAL DESIGN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TEMPERATURE;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HYDROGEN-ION CONCENTRATION; PROTAMINES; REPRODUCIBILITY OF RESULTS;

EID: 84862777856     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.01.002     Document Type: Article

References (22)

1. Hoffmann J.A., Chance R.E., Johnson Purification M.G. Analysis of the major components of chum salmon protamine contained in insulin formulations using high performance liquid chromatography. Protein expression and purification 1990, 1:127-133.
2. Lochmann D., Stadlhofer S., Weyermann J., Zimmer A. New protamine quantification method in microtiter plates using o-phthaldialdehyde/N-acetyl-l-cysteine reagent. Int. J. Pharm. 2004, 283:11-17.
3. McKay D.J., Renaux B.S., Dixon G.H. Rainbow trout protamines: amino acid sequences of six distinct proteins from a single testis. Eur. J. Biochem. 1986, 159:361-366.
4. Yang V.C., Fu Y-Y., Teng C.-L.C., Ma S.C., Shanberge J.N. A method for the quantitation of protamine in plasma. Thromb. Res. 1994, 74:427-434.
5. Boulikas T., Martin F. Histones, protamine and polylysine but not poly (E:K) enhance transfection efficiency. Int. J. Onc. 1997, 10:317-322.
6. Junghans M., Kreuter J., Zimmer A. Phosphodiester and phosphorothioate oligonucleotide condensation and preparation of antisense nanoparticles. Biochim. Biophys. Acta 2001, 1544:177-188.
7. Snycerski A., Dudkiewicz-Wilczynska J., Tautt J. Determination of protamine sulphate in drug formulations using high performance liquid chromatography. J. Pharm. Biomed. Anal. 1998, 18:907-910.
8. Hvass A., Skelbaek-Pedersen.B. Determination of protamine peptides in insulin drug products using reversed phase high performance liquid chromatography. J. Pharm. Biomed. Anal. 2005, 37:551-557.
9. Molnár I., Monks K.E., Rieger H.-J. Expanding the term design space in high performance liquid chromatography (I). J. Pharm. Biomed. Anal. 2011, April.
10. Charoo N.A., Shamsher A.A.A., Zidan A.S., Rahman Z. Quality by design approach for formulation development: a case study of dispersible tablets. Int. J. Pharm. 2011, 10.1016/j.ijpharm.2011.12.024.
11. Mennini N., Furlanetto S., Cirri M., Mura P. Quality by design approach for developing chitosan-Ca-alginate microspheres for colon delivery of celecoxib-hydroxypropyl--cyclodextrin-PVP complex. Eur. J. Pharm. Biopharm. 2012, 8:67-75.
12. International Conference on Harmonization Tripartite Guideline 'Q8, Pharmaceutical Development', Step 4 version, 2009, 1-28. Available at; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf.
13. Gavin P.F., Olsen B.A. A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603). J. Pharm. Biomed. Anal. 2008, 46:431-441.
14. McBrien M. Practical implications of quality by design to chromatographic method development. Chromatogr. Today 2010, May/June:30-33.
15. International Conference for Harmonisation (ICH) Guidelines for Industry, ICH Q2(R1), Validation of Analytical Procedures: Methodology, (2005).
16. Ye C., Terfloth G., Li Y., Kord A. A systematic stability evaluation of analytical RP-HPLC columns. J. Pharm. Biomed. Anal. 2009, 50:426-431.
17. Li W., Rasmussen H.T. Strategy for developing and optimizing liquid chromatography methods in pharmaceutical development using computer-assisted screening and Plackett-Burman experimental design. J. Chromatogr. A 2003, 1016:165-180.
18. Meek J.L., Rossetti Z.L. Factors affecting retention and resolution of peptides in high-performance liquid chromatography. J. Chromatogr. 1981, 211:15-28.
19. Wu A.B., Huang M.C., Ho H.O., Yeh G.C., Sheu M.T. Investigation on liquid chromatographic separation of basic compounds using silica column with aqueous/organic mobile phase containing triethylamine and acetic acid. Biomed. Chromatogr. 2004, 18:443-449.
20. Ragonese R., Macka M., Hughes J., Petocz P. The use of the Box-Behnken experimental design in the optimization and robustness testing of a capillary electrophoresis method for the analysis of ethambutol hydrochloride in a pharmaceutical formulation. J. Pharm. Biomed. Anal. 2002, 27:995-1007.
21. Torrealday N., Gonzalez L., Alonso R.M., Jimenez R.M., Ortiz Lastra E. Experimental design approach for the optimization of a HPLC-fluorimetric method for the quantitation of the angiotensin II receptor antagonist telmisartan in urine. J. Pharm. Biomed. Anal. 2003, 32:847-857.
22. Khamanga S.M., Walker R.B. The use of experimental design in the development of an HPLC-ECD method for the analysis of captopril. Talanta 2011, 83:1037-1049.